Wegovy vs Mounjaro UK - Cheapest Price From £69.00

Our Pricing

Wegovy vs Mounjaro: Clinical Evidence and UK Treatment Comparison

Published on: June 03, 2026

When comparing wegovy vs mounjaro uk weight loss options, understanding the clinical trial data is essential for making an informed choice. Both medications are MHRA-licensed injectable treatments that work through related but distinct mechanisms, with Mounjaro (tirzepatide) offering dual-hormone action and Wegovy (semaglutide) targeting a single pathway. At Cured Pharmacy, our UK-registered prescribers assess which treatment aligns with your medical history, weight loss goals, and individual response factors.

How Wegovy and Mounjaro Work Differently

Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the glucagon-like peptide-1 hormone naturally produced in your gut [1]. This hormone slows gastric emptying, reduces appetite, and improves blood sugar regulation. Wegovy has been available in the UK since 2023 and is administered as a once-weekly subcutaneous injection, with doses gradually increased from 0.25mg to a maintenance dose of 2.4mg.

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management [2]. By activating both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors, tirzepatide produces a more comprehensive metabolic effect. This dual action appears to enhance weight loss beyond what single-pathway treatments achieve, though individual responses vary based on metabolic factors and adherence to lifestyle modifications.

Clinical Trial Results: Wegovy vs Mounjaro UK Evidence

The STEP 1 trial demonstrated that participants taking Wegovy 2.4mg achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. Approximately 50.5% of participants lost at least 15% of their initial body weight, and 86.4% achieved at least 5% weight loss when combined with lifestyle interventions.

In the SURMOUNT-1 trial, Mounjaro participants on the 15mg maintenance dose achieved an average weight reduction of 20.9% over 72 weeks, significantly higher than the comparator group [2]. At the 10mg dose, average weight loss was 19.5%, and even the 5mg dose produced 15% average reduction. These results represent the highest weight loss outcomes recorded in any obesity medication trial to date, though it's important to note that trial conditions include intensive dietary counselling and monitoring not always replicated in routine clinical practice.

Head-to-Head Comparison Data

While no large-scale direct comparison trial between Wegovy and Mounjaro has been published, indirect comparisons using similar trial populations suggest tirzepatide produces approximately 5-6 percentage points greater weight loss on average [3]. However, individual responses vary considerably based on baseline BMI, metabolic health, adherence to injection schedules, and concurrent lifestyle modifications. Your UK prescriber will consider these factors when recommending treatment, and some patients may achieve excellent results with either medication.

Side Effects and Tolerability Profile

Both medications share a similar side effect profile due to their GLP-1 activity, with gastrointestinal symptoms being most common [4]. Nausea affects approximately 44% of Wegovy users and 29-34% of Mounjaro users during dose escalation, though symptoms typically diminish after 4-8 weeks as the body adapts. Other frequent side effects include diarrhoea, constipation, vomiting, and abdominal discomfort.

The gradual dose titration schedule built into both treatments helps minimise these effects. Wegovy escalates over 16-20 weeks to reach the 2.4mg maintenance dose, while Mounjaro increases every four weeks from 2.5mg to the target dose. Approximately 4-7% of participants discontinue treatment due to gastrointestinal side effects in clinical trials [1][2]. Serious adverse events are rare but include potential pancreatitis, gallbladder disease, and hypoglycaemia when combined with certain diabetes medications.

Managing Side Effects in Clinical Practice

Our clinical team at Cured Pharmacy provides detailed guidance on minimising side effects through dietary adjustments, including smaller portions, avoiding high-fat meals, and staying well-hydrated. Taking the injection on the same day each week and not advancing to the next dose until current side effects have resolved can significantly improve tolerability. If you experience persistent vomiting, severe abdominal pain, or signs of pancreatitis, contact your prescriber immediately for clinical review.

Dosing Schedules and Administration

Wegovy is administered once weekly via subcutaneous injection in the abdomen, thigh, or upper arm. The standard dose escalation follows this schedule: 0.25mg for weeks 1-4, 0.5mg for weeks 5-8, 1mg for weeks 9-12, 1.7mg for weeks 13-16, and 2.4mg maintenance from week 17 onwards. Each pre-filled pen contains a single dose, and injection technique is straightforward with minimal training required.

Mounjaro follows a similar once-weekly injection schedule but with different dose increments: starting at 2.5mg for four weeks, then increasing to 5mg, 7.5mg, 10mg, 12.5mg, and potentially 15mg based on individual response and tolerability [2]. The KwikPen device used for Mounjaro features a hidden needle and simple push-button mechanism, making self-administration accessible for most patients. Your UK prescriber determines the optimal maintenance dose based on weight loss progress and side effect profile after the initial titration period.

Cost Comparison and UK Availability

At Cured Pharmacy, Mounjaro is available from £124.99 per month, with pricing varying based on your prescribed dose following clinical assessment. Both medications require a prescription from a UK-registered prescriber, and our online consultation process takes under three minutes to complete. Unlike some providers, we display transparent pricing before you begin your assessment, ensuring no unexpected costs during the prescription process.

Supply availability for both treatments has improved significantly throughout 2024 following earlier shortages. We maintain consistent stock levels of all licensed doses and provide discreet next-day delivery across the UK. All medications dispensed by Cured Pharmacy are sourced directly from UK-licensed wholesalers and meet MHRA quality standards. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), oversees all dispensing to ensure pharmaceutical care meets General Pharmaceutical Council requirements.

Insurance and NHS Availability

NHS prescribing of both Wegovy and Mounjaro is currently restricted to specialist weight management services due to NICE guidance limitations and budget constraints. Most UK patients access these treatments through private prescription, either via online pharmacies or private GP services. Some private health insurance policies may cover weight loss medications when prescribed for obesity-related health conditions, though coverage varies by provider and policy terms. Check with your insurer regarding reimbursement eligibility before starting treatment.

Which Treatment Is Right for You?

Choosing between wegovy vs mounjaro uk options depends on multiple clinical factors that your prescriber will assess during consultation. Patients with higher baseline BMI (over 35) or those who haven't achieved adequate results with previous weight loss treatments may benefit from Mounjaro's enhanced efficacy profile [3]. However, Wegovy remains an excellent first-line option with extensive real-world safety data and proven cardiovascular benefits in long-term studies.

Your medical history plays a crucial role in treatment selection. Both medications are contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Patients with history of pancreatitis, severe gastroparesis, or inflammatory bowel disease require careful evaluation before starting either treatment. Our UK prescribers review your complete medical profile, current medications, and weight loss goals to recommend the most appropriate option, and treatment can be adjusted if initial response is suboptimal.

Monitoring and Long-Term Success

Successful weight management with either medication requires ongoing monitoring and lifestyle modifications. We recommend regular follow-up consultations every 12 weeks to assess progress, adjust dosing if needed, and address any concerns. Clinical trials show that weight loss plateaus typically occur around 60-72 weeks, after which maintaining lifestyle changes becomes essential for sustaining results [1][2]. Both medications are licensed for long-term use, and discontinuation often results in weight regain, making indefinite treatment necessary for many patients to maintain clinical benefits.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
3. Urva, S., et al. (2022). Comparison of the efficacy of tirzepatide and semaglutide, both at 15 mg, in the SURPASS-2 trial. Diabetes, Obesity and Metabolism, 24(9), 1780–1783. https://doi.org/10.1111/dom.14755 [accessed 13 August 2026]
4. Smits, M. M., & Van Raalte, D. H. (2021). Safety of Semaglutide. Frontiers in Endocrinology, 12, 645563. https://doi.org/10.3389/fendo.2021.645563 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to lifestyle modifications alongside medication use.